The article highlights the emergent use of upconverting nanoparticles as tools for the near infrared photoactivation of transition metal complexes, identifying opportunities and challenges of this approach in the context of medicinal inorganic chemistry.
Introduction
The portion of the electromagnetic spectrum that spans from UV to near infrared (NIR) has wavelength-dependent effects on biomolecules and displays different tissue penetration capabilities, as a result of the distinct absorption properties that tissue constituents have. 1 As shown in Fig. 1 where he is exploring the use of upconverting nanoparticles as tools for the near infrared photoactivation of metal-based prodrugs.
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and Luca Salassa (left) and for limiting photodamage. In fact, prolonged exposure to short-wavelength light (e.g. UVC-A) can seriously harm cells by inducing photochemical reactions. On the other hand, water absorption is predominant at wavelengths higher than 1000 nm, reducing the penetration of light and causing overheating of biological components.
For this reason, the so-called "phototherapeutic window" is considered to be in the range 650-1000 nm. Light of approx. 800 nm is ideal for use in biological systems since it does minimize the excitation of biomolecules and water heating. As well documented by several review articles, 3 the success of photodynamic therapy (PDT) 4 has prompted medicinal inorganic chemists to look at the unique photophysics and photochemistry of metal complexes and to devise new lightactivatable prodrugs which improve the selectivity of metalbased anticancer agents. Various design concepts have been adopted in the development of photoactivatable metal complexes. Apart from their use as alternative PDT photosensitizers, metal-based prodrugs have also been designed to exert their antineoplastic action through mechanisms that are different from PDT, i.e. oxygen independent, such as for example DNA-photobinding or photouncaging of bioactive molecules. However, oxygen sensitization is often concurrent with photochemical transformation of the prodrug agent. The great majority of light-activatable metal-based prodrugs are inactive upon NIR light excitation, since they typically require high-energy UV-visible light to trigger a photochemical response. Such an intrinsic feature of metal complexes hampers somewhat their current progress towards more advanced preclinical and clinical stages. In principle, NIR light sources would favour the use of photoactivatable metal-based prodrugs in a wider range of cancers and allow tuning light doses during treatment. For example, the maximum permissible exposure (MPE) of human skin for visible light (400-700 nm) is 0. 20 Excluding from the discussion inert metal-based systems that work as PDT photosensitizers, the synthetic design of metal complexes that can be light-activated in the phototherapeutic window has been extremely challenging. Very few exceptions have been reported due to the trade-off that exists between achieving good absorption in the red part of the spectrum and maintaining high photoreactivity. 8 This requires an appropriate choice of ligands (e.g. dye-like) and optimal tuning of ligand and metal orbital energies, which in practice is not always feasible. Indeed, photoactivation of metal complexes in the phototherapeutic window or nearby has been reported; however, generally such systems exploit weak absorption bands, whose intensity is hard to improve.
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As an alternative photoactivation approach, inorganic nanomaterials offer outstanding optical features which can serve to shift excitation wavelengths for metal complexes into the red and near infrared regions. Moreover, the versatile surface chemistry of nanomaterials provides a myriad of strategies to develop innovative metal-based prodrug carriers for photochemotherapy.
In this Frontier article we discuss recent research efforts aimed at combining a specific class of nanomaterials, that is, upconverting nanoparticles, with photoactivatable metal complexes of interest in medicinal inorganic chemistry and carry out near infrared photoactivation. For the sake of brevity, we have omitted from this summary the early pioneering work on quantum dots and the promising results obtained by triplettriplet annihilation upconversion approaches, which have been reviewed elsewhere.
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Upconverting nanoparticles
In recent years, upconverting nanoparticles (UCNPs) have been intensely investigated for application as imaging probes and drug carriers in biology and medicine, due to their exceptional optical and chemical properties. UCNPs are lanthanide-doped crystals which absorb and convert low-energy NIR photons (980 or 808 nm) into high energy UV-visible light.
11 In UCNPs, upconversion is a non-linear optical luminescence phenomenon where two or more photons are absorbed by a material and a single photon of shorter wavelength (anti-Stokes shift) is subsequently emitted. Various mechanisms can contribute to upconversion emission, including excited state absorption (ESA), energy transfer upconversion (ETU) and photon avalanche (PA), ETU being the dominating pathway in UCNPs. 12 Typically, the brightest UCNPs are composed of a fluorine inert matrix (NaREF 4 , RE = Y, Gd, Lu), which offers doping sites for optically active lanthanide ions. Ions employed as ca. <5 mol%). Fig. 2 shows the emission spectra and energy level diagrams for typical NaYF 4 :Yb,Tm and NaYF 4 :Yb,Er UCNPs. Upconversion emission in these UCNPs profit from the good absorption cross-sections of Yb 3+ at 980 nm and can be obtained by excitation with relatively low power (0.1-10
Upconversion luminescence increases with the size of UCNPs. For instance, quantum yield values for NaYF 4 :Yb,Er (20%/2%) with different diameters (from 10 to 100 nm) span from 0.005% to 0.3%. Growing a protective shell with different thicknesses and compositions around an active core serves to modulate and/or improve the optical properties of UCNPs. In fact, shell passivation reduces surface defects in nanocrystals and protects optically active lanthanide ions from non-radiative deactivation by solvents and organic capping ligands which cover the UCNP surface. Core@shell nanoparticles are generally brighter than core-only nanoparticles, with an increase in upconverted luminescence up to 10-20 folds. 13 Importantly, co-doping of UCNPs with Yb 3+ and Nd 3+ donor ions affords nanoparticles that can be excited at 808 nm (reduced water heating) where Nd 3+ has a large absorption cross section. 12 The principal approach employed to fabricate bright UCNPs is the thermal decomposition method, which produces nanoparticles with controlled composition, crystalline phase and size (detailed studies on the crystalline properties and growth mechanism of UCNPs have been reported for example by Haase and co-workers). 14 
NIR activation of metal complexes by UCNPs
The interest of inorganic medicinal chemists in UCNPs began to show an upsurge recently (around 2012), motivated by the prospect that upconverted UV-visible emissions might activate transition metal complexes adsorbed or anchored onto the surface of nanoparticles by means of NIR-light excitation. Few, yet encouraging, systems have demonstrated that Er-and Tmdoped UCNPs indeed provide a novel route for near infrared photochemistry in metal complexes. These early examples involve so far four transition metals, Mn, Fe, Ru and Pt, all of which undergo chemical transformation upon UV-visible light excitation. The primary and basic objectives of these studies were to explore different anchoring strategies for loading photoactivatable metal complexes onto UCNPs and evaluate the photochemical behaviour of the resulting nanomaterials under NIR light irradiation. Evidently, several of the systems reported here should be improved both in terms of photoreactivity and applicability in biological environments for use in photochemotherapy. However, they represent a benchmark which may serve to develop new light-activation approaches and to improve the design of UCNP-based nanomaterials for more advanced applications in biology and medicine.
In 2012 Ford and Zhang first reported, in a joint article, the NIR-light activation of the photoactive Roussin's black salt anion, Na[Fe 4 S 3 (NO) 7 ] (RBS). 15 This inorganic salt has a broad absorption band in the visible region (400-600 nm) and has been extensively investigated as a nitric oxide (NO) photo- releasing moiety (Fig. 3a) . Fig. 2b) . 18 CO is an attractive small molecule for phototherapeutic applications due to its cytoprotective and anti-inflammatory properties. 19 The (Fig. 4b) . 26 A biocompatible (FDA-approved) PEGylated phospholipid was coupled with the Pt IV complex to decorate UCNPs with prodrug molecules. In the nanocarrier, the oleate chains capping UCNPs hydrophobically interact with the tails of the PEGylated phospholipid, while the hydrophilic PEG units of the polymer are exposed to the solvent, conferring further stabilization and water solubility on the system. After 3.5 h of NIR-light irradiation, the Pt IV prodrug agent loaded onto the nanocarrier was fully converted into Pt II species, as determined by XPS and NMR analyses of the supernatant solution (separated from the UCNP-containing pellet by centrifugation). advantage of the aliphatic chain of the C 18 H 37 CN ligands to promote strong hydrophobic interactions with the oleic acid ligands of UCNPs. Afterwards, UCNPs were capped with PEG to improve aqueous solubility. ICP-AES indicated that a loading capability of 0.01 g of complex per gram of particle was achieved. The resulting nanocarriers released the two nitrile monodentate ligands upon 980 nm excitation (3 W cm could induce doxorubicin release from the system through a thick pork tissue. Upon 10-30 min of NIR-light exposure (0.35 W cm −2 ), the nanocarrier (300 μg ml −1 ) incubated in HeLa cells decreased the cell viability to 30-40%, while the system displayed no toxicity under dark conditions. Control experiments under NIR light irradiation also demonstrate that UCNPs loaded with the Ru complex without doxorubicin did not affect cell viability. Remarkably, the maximum light intensity used to photoactivate the Wu nanoconstruct was lower than the maximum permissible exposure of skin.
Conclusions and future outlook
NIR-light photochemical activation of biologically relevant metal complexes is still in its infancy. UCNPs hold great promise as NIR-light sensitizers and the examples reported indeed show that UCNPs can shift activation wavelengths of metal-based prodrugs into the so-called phototherapeutic window. However, systems based on UCNPs and metal complexes work so far at a proof-of-concept level and many more obstacles need to be overcome to advance forward. In the first instance, lowering the laser power density employed during light administration and the light exposure time are fundamental requirements. In this context, it will be crucial to improve the upconversion efficiency of UCNPs and optimize the photochemical response of nanoconstructs for maximal efficiency. The ultimate goal is to achieve excitation intensities that are lower than 0.73 W cm −2 . Although much needs to be improved, Wu's group has shown that the choice of the photosensitive compounds is critical and that activation of ruthenium metal complexes can be achieved with such intensities or lower and through tissues. 31, 32 In addition, NIR-sensitive hybrid materials based on UCNP and metal complexes have to face and tackle challenges that are typically encountered in the development of nanodelivery systems and nanodrugs. These include aspects of the chemical design such as optimizing the solubility of nanoplatforms and their loading with metal-based drugs. Moreover, systematic biological studies are fundamental to obtain a thorough knowledge of the interactions between UCNPs and the healthy and tumour cell microenvironments, understanding how to improve materials circulation and distribution in organisms, and tailoring their toxicity mechanism of action to specific tumours. 33 Therefore, many more years of investigation are required to eventually translate the use of UCNPs into a real clinical application. Yet, NIR-activated photochemistry of metal complexes may lead, in the process, to new discoveries and also provide innovative solutions for other applications.
In addition to their use as phototriggers and luminescent probes, UCNP nanomaterials also offer outstanding opportunities for other imaging modalities. Their composition and structural features make UCNPs suitable for magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Often these modalities have been successfully exploited simultaneously in one UCNP. 11a Together with the good biocompatibility and relatively low toxicity profile in vitro and in vivo, 34 these features make UCNPs worth investigating for application in theranostics.
